{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:07:58Z","timestamp":1793156878689,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023286","name":"Junior League of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","award":["NCT04204980"],"award-info":[{"award-number":["NCT04204980"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ekir.2024.08.020","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T19:57:38Z","timestamp":1724702258000},"page":"3250-3264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Open-Label Phase 1\/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation"],"prefix":"10.1016","volume":"9","author":[{"given":"Caroline","family":"Pilon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Joher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Usureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Boueilh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Taupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Thiolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vissal David","family":"Kheav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Canoui-Poitrine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryvonnick","family":"Carmagnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Grimbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Matignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.08.020_bib1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/TP.0000000000003410","article-title":"The introduction of cPRA and its impact on access to deceased donor kidney transplantation for highly sensitized patients in Australia","volume":"105","author":"Sypek","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.08.020_bib2","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1111\/ajt.17180","article-title":"The new French kidney allocation system for donations after brain death: rationale, implementation, and evaluation","volume":"22","author":"Audry","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.humimm.2016.08.008","article-title":"Why do we have the kidney allocation system we have today? a history of the 2014 kidney allocation system","volume":"78","author":"Stegall","year":"2017","journal-title":"Hum Immunol"},{"key":"10.1016\/j.ekir.2024.08.020_bib4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1681\/ASN.2014090894","article-title":"Immune sensitization and mortality in wait-listed kidney transplant candidates","volume":"27","author":"Sapir-Pichhadze","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.08.020_bib5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/ajt.13770","article-title":"Changes in deceased donor kidney transplantation one year after KAS implementation","volume":"16","author":"Stewart","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.784472","article-title":"Editorial: Sensitization and Desensitization in Organ Transplantation","volume":"12","author":"Anwar","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.08.020_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ajt.15873","article-title":"Experimental modeling of desensitization: what have we learned about preventing AMR?","volume":"20","author":"Kwun","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib8","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(16)31595-1","article-title":"Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis","volume":"389","author":"Manook","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.08.020_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2024.08.020_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003464","article-title":"Efficacy of daratumumab in refractory primary Sj\u00f6gren disease","volume":"9","author":"Nocturne","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ekir.2024.08.020_bib12","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.08.020_bib13","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2024.08.020_bib14","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1097\/TP.0000000000004719","article-title":"New desensitization strategy: daratumumab for highly sensitized pediatric heart transplant candidate","volume":"107","author":"Baez Hernandez","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.08.020_bib15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.healun.2022.06.017","article-title":"Daratumumab provides transient response of antibody mediated rejection post pediatric orthotopic heart transplantation","volume":"41","author":"Fenton","year":"2022","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib16","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/TP.0000000000003505","article-title":"Daratumumab for antibody-mediated rejection in heart transplant-a novel therapy: successful treatment of antibody-mediated rejection","volume":"105","author":"Aguilera","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2024.08.020_bib17","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.ajt.2023.06.018","article-title":"Daratumumab for antibody-mediated rejection: is it time to target the real culprit?","volume":"23","author":"de Nattes","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11771","article-title":"A\u00a0novel daratumumab-based regimen for desensitization in highly HLA-presensitized patients awaiting kidney transplantation","volume":"36","author":"Zhao","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2024.08.020_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.08.020_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686271","article-title":"Current approaches to desensitization in solid organ transplantation","volume":"12","author":"Schinstock","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.08.020_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A\u00a0randomized Phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.08.020_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ajt.15613","article-title":"A\u00a0prospective, iterative, adaptive trial of carfilzomib-based desensitization","volume":"20","author":"Tremblay","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2017060679","article-title":"Control of humoral response in renal transplantation by Belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk","volume":"29","author":"Leibler","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.08.020_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajt.15585","article-title":"The impact of Belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients","volume":"20","author":"Parsons","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib26","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/ajt.15229","article-title":"Belatacept in renal transplant recipient with mild immunologic risk factor: a pilot prospective study (Belacor)","volume":"19","author":"Leibler","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.08.020_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002742","article-title":"Daratumumab for the treatment of refractory ANCA-associated vasculitis","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ekir.2024.08.020_bib29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00467-020-04811-0","article-title":"A\u00a0global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome","volume":"36","author":"Dossier","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.08.020_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14544","article-title":"Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab","volume":"27","author":"Delbet","year":"2023","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.08.020_bib32","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2024.08.020_bib33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/tid.12593","article-title":"Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients","volume":"18","author":"Augusto","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ekir.2024.08.020_bib34","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1681\/ASN.2020050566","article-title":"Death after kidney transplantation: an analysis by era and time post-transplant","volume":"31","author":"Ying","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.08.020_bib35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/ndt\/gfv007","article-title":"Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry","volume":"30","author":"Vogelzang","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib36","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41409-019-0664-4","article-title":"Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation","volume":"55","author":"Rautenberg","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41409-021-01507-3","article-title":"Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation","volume":"57","author":"Martino","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2024.08.020_bib38","volume":"11","author":"S\u00fcsal","year":"2023"},{"key":"10.1016\/j.ekir.2024.08.020_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503951","article-title":"Daratumumab for treatment of antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"9","author":"Spica","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.ekir.2024.08.020_bib40","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2024.08.020_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.08.020_bib42","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1681\/ASN.2022030286","article-title":"Effector memory-expressing CD45RA (TEMRA) CD8+ T cells from kidney transplant recipients exhibit enhanced purinergic P2X4 receptor-dependent proinflammatory and migratory responses","volume":"33","author":"Doan Ngoc","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.08.020_bib43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/tan.14781","article-title":"Clinical utility of serial serum dilutions for HLA antibody interpretation","volume":"100","author":"Tambur","year":"2022","journal-title":"HLA"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:48:43Z","timestamp":1778892523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924019053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2468024924019053"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.08.020","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-Label Phase 1\/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}